Healthcare Industry News: Regeneration Technologies
News Release - July 24, 2007
AxoGen, Inc. Announces the First Human Nerve Graft ImplantALACHUA, Fla.--(HSMN NewsFeed)--An advanced nerve graft from AxoGen(TM) was implanted to repair a severed nerve in a 38 year old male who suffered a traumatic injury to his face. On July 20, 2007, the Mayo Clinic (Rochester, MN) plastic surgery team led by Dr. Steven L. Moran and Dr. Samir Mardini repaired the injured facial nerve to enable the patient to regain use of his facial muscles. The nerve repair was accomplished using the graft to connect the severed nerve root to three nerve branches using only one graft. Dr. Moran stated, "No other commercially available product could have been used in this application." The alternative would have been to transplant a nerve from another site of the patients body to the severed nerve; thus, requiring additional surgery. Dr. Moran further remarked, "The graft had superior handling characteristics to an autograft."
Peripheral nerves are the communication system of the body, allowing signals for motion or touch to be transmitted between the muscles and the brain. The AXOGEN nerve graft enables the repair and regeneration of peripheral nerves. It is an allograft nerve that is minimally processed to preserve the three dimensional structure and growth promoters while clearing the nerve graft from cellular materials and growth inhibitors. The resulting nerve graft provides a pathway for nerve regeneration without requiring immunosuppression.
AxoGen, Inc., based in Alachua, Florida, is a privately held company pioneering the commercialization of peripheral nerve grafting and nerve Regeneration Technologies. AxoGen is focused in the advancement of peripheral nerve repair by creating a unique combination of patented technologies and a rich pipeline of new products to change the standard of care for patients with injured peripheral nerves.
Visit AxoGen at: www.axogeninc.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.